ONYX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Onyx Pharmaceuticals, Inc.

Levi & Korsinsky is investigating the Board of Directors of Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”) (NasdaqGS: ONXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Amgen (Nasdaq: AMGN).

Click here to learn more about the investigation http://zlk.9nl.com/onyx-pharmaceuticals-onxx/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Onyx shareholders will receive $125.00 for each share of Onyx stock they own. The investigation concerns whether the Onyx Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Amgen is underpaying for Onyx shares. In particular, at least one analyst set a price target of $160.00 per Onyx share.

If you and own Onyx common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/onyx-pharmaceuticals-onxx/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan